International reference: 1 US FDA recall for this ingredient

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes (diclazuril)

US-market enforcement records (OpenFDA), shown for reference - not specific to this product in Tanzania.

Registered Tanzania · TMDA

Diclacox

Diclazuril 1.0 %w/w

TZ 16 V 0007 Solution 1.0 INN generic

What it does

Diclazuril is a medication used to treat certain parasitic infections in animals. It helps eliminate these parasites from the body.

Commonly used for: parasitic infections in animals

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.

Sourcing - Kenya only

Registration & product details

Registration no.
TZ 16 V 0007
Registration date
2026-02-27
Expiry date
2031-02-26
Status
Registered/Compliant
Active ingredient
Diclazuril 1.0 %w/w
Dosage form
Solution
Strength
1.0
Pack size
-
Therapeutic class
-
RxNorm RxCUI
1368201
Manufacturer / MAH
Biove
Applicant / LTR
LAPROVET
Country of origin
FRANCE
Manufacturer location
3 Rue de Lorraine, 62510 Arques, France

Source: Tanzania Medicines and Medical Devices Authority · fetched 2026-04-30 08:11:03 · updated 2026-09-17 03:00:44

Disclaimer: This information is sourced from Tanzania Medicines and Medical Devices Authority (Tanzania). Always consult a qualified healthcare professional before using any medication.

About this medicine

Diclazuril is a medication used to treat certain parasitic infections in animals. It helps eliminate these parasites from the body.

What it treats

  • parasitic infections in animals

How it works

Diclazuril works by stopping the growth and reproduction of parasites in the body.

Who it's for

This medication is generally used for animals affected by specific parasitic infections.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: diclazuril

BNF-referenced

Diclazuril is a triazinone compound primarily utilized as an anticoccidial agent in veterinary medicine. It is effective against various species of Eimeria, which are protozoan parasites that cause coccidiosis in livestock and poultry. The drug acts to disrupt the life cycle of the parasites, leading to their death and reducing clinical signs of the disease.

Indications

  • Coccidiosis in poultry
  • Coccidiosis in livestock
  • Prevention of coccidiosis in young animals

Dosage

Children: Refer to the BNF for Children for appropriate dosing based on age, weight, and specific conditions.

Adults: Refer to the BNF for specific dosing recommendations based on the type of animal and severity of the condition.

Mechanism of action

Diclazuril functions by inhibiting mitochondrial respiration in the apicomplexan parasites. It disrupts the electron transport chain, leading to decreased ATP production, which is essential for the parasite's survival and reproduction.

Pharmacodynamics

The pharmacodynamics of diclazuril involve its selective action on the coccidian parasites, leading to effective inhibition of their growth and reproduction. The drug primarily affects the intracellular stages of the parasites, with a significant impact on the sporulated oocysts and meronts. This selective toxicity limits its effects on host cells, making it a preferred agent in veterinary medicine.

Pharmacokinetics

Diclazuril is absorbed well when administered orally, with peak plasma concentrations occurring within a few hours post-administration. It is metabolized in the liver and has a relatively long half-life, allowing for once-daily dosing. The drug is primarily excreted in feces, with minimal renal excretion. Its pharmacokinetic profile supports effective treatment with sustained therapeutic levels.

Adverse effects

  • Gastrointestinal disturbances
  • Neurological effects
  • Hypersensitivity reactions

Precautions

  • Use with caution in animals with known hypersensitivity to the drug.
  • Monitor for signs of toxicity, especially in the presence of hepatic impairment.

Pregnancy

There is limited information on the use of diclazuril in pregnant individuals. Consult relevant guidelines for specific recommendations.

Breast-feeding

Limited data available; consult relevant guidelines for specific recommendations regarding use during breastfeeding.

Storage

Store in a cool, dry place, protected from light.

Formulations

  • Oral formulation
  • Injectable formulation
PubChem / pathway

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

Molecular reference: diclazuril

PubChem CID 456389

Molecular formula: C17H9Cl3N4O2

Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.

This drug in other countries

The same active ingredient registered across other registries we cover - including different brands.

Ghana 1 product